Can anyone explain this?A biotech stock that has a potential blockbuster drug and partnerships to trial the drug with other big pharma products is trading at a market cap of $50M?
I don't get it. One analyst shows ONC earning over $1 in EPS in 2022 and another is forecasting over $3... even with a fair P/E multiple of 20x that's a $20-$60 stock in 2-3 years time... what's the bear case on this?